Drug Shortage Report for HEPARIN SODIUM INJECTION, USP
| Report ID | 253982 |
| Drug Identification Number | 02264307 |
| Brand name | HEPARIN SODIUM INJECTION, USP |
| Common or Proper name | HEPARIN SODIUM INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | HEPARIN SODIUM |
| Strength(s) | 10000UNIT |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
| Packaging size | 5mL |
| ATC code | B01AB |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2025-04-02 |
| Estimated end date | 2025-05-23 |
| Actual end date | 2025-05-13 |
| Shortage status | Actual shortage |
| Updated date | 2025-05-12 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we have encountered a supply interruption on our Heparin Sodium Injection, USP 10 000 USP units/mL MD Vial 5 mL effective April 2, 2025, until May 23, 2025. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2025-05-12 | French | Compare |
| v5 | 2025-05-12 | English | Compare |
| v4 | 2025-04-30 | French | Compare |
| v3 | 2025-04-30 | English | Compare |
| v2 | 2025-04-03 | French | Compare |
| v1 | 2025-04-03 | English | Compare |
Showing 1 to 6 of 6